Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ziopharm appoints James Huang to board of directors » 08:42
07/22/20
07/22
08:42
07/22/20
08:42
ZIOP

Ziopharm

$3.35 /

-0.07 (-2.05%)

Ziopharm Oncology…

Ziopharm Oncology announced the appointment of James Huang to the Company's Board of Directors. Huang is currently a Managing Partner at Kleiner Perkins Caufield & Byers China and has founded and financed several innovative life sciences companies. He is also Founding Partner of Panacea Venture, which formed TriArm Therapeutics, the funding partner for Ziopharm's joint venture, Eden BioCell.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.35 /

-0.07 (-2.05%)

ZIOP Ziopharm
$3.35 /

-0.07 (-2.05%)

07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
ZIOP Ziopharm
$3.35 /

-0.07 (-2.05%)

  • 05
    Feb
ZIOP Ziopharm
$3.35 /

-0.07 (-2.05%)

ZIOP Ziopharm
$3.35 /

-0.07 (-2.05%)

Recommendations
Ziopharm took 'important step' with start of CAR-T study, says Lake Street » 09:11
07/10/20
07/10
09:11
07/10/20
09:11
ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

Lake Street analyst…

Lake Street analyst Thomas Flaten said a combination of planning issues, manufacturing optimization and the pandemic delayed initiation of Ziopharm's Phase 1 study of its CD19 CAR-T program and he sees the start of the trial as "an important step, while adding that "results will ultimately determine the success of the study." Flaten, who acknowledges that "it will be some time until data is available," keeps a Buy rating and $7 price target on Ziopharm shares.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

  • 05
    Feb
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

On The Fly
Fly Intel: Pre-market Movers » 09:06
07/10/20
07/10
09:06
07/10/20
09:06
GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, ALV

Autoliv

$63.32 /

-0.9 (-1.40%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, GBX

Greenbrier

$21.75 /

-0.895 (-3.95%)

, SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, BYND

Beyond Meat

$141.13 /

-3.735 (-2.58%)

, SC

Santander Consumer

$17.32 /

-1.005 (-5.48%)

, FSLY

Fastly

$102.67 /

+6.52 (+6.78%)

, RIG

Transocean

$1.90 /

-0.12 (-5.96%)

, CNTG

Centogene

$17.06 /

-2.1 (-10.96%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

07/10/20 Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ALV Autoliv
$63.32 /

-0.9 (-1.40%)

07/09/20 Goldman Sachs
Autoliv initiated with a Buy at Goldman Sachs
06/19/20 JPMorgan
Autoliv price target raised to $63 from $55 at JPMorgan
06/11/20 Evercore ISI
Autoliv upgraded to In Line from Underperform at Evercore ISI
05/28/20 Wolfe Research
Autoliv downgraded to Peer Perform from Outperform at Wolfe Research
MATX Matson
$27.46 /

-0.69 (-2.45%)

07/10/20 Stifel
Matson price target raised to $44 from $35 at Stifel
04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

04/28/20 Susquehanna
Greenbrier downgraded to Negative from Neutral at Susquehanna
04/08/20 KeyBanc
Greenbrier price target lowered to $30 from $38 at KeyBanc
01/14/20 Wells Fargo
Greenbrier downgraded to Underweight from Equal Weight at Wells Fargo
11/08/19 Susquehanna
Greenbrier downgraded to Neutral from Positive at Susquehanna
SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

07/10/20 Craig-Hallum
Simulations Plus price target raised to $75 from $56 at Craig-Hallum
06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

07/10/20 Citi
Citi starts Beyond Meat with Sell, sees 15% share downside
07/10/20 Citi
Beyond Meat initiated with a Sell at Citi
07/09/20 Bernstein
Beyond Meat price target raised to $133 from $118 at Bernstein
06/29/20
Fly Intel: Top five analyst downgrades
SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

06/03/20 Stephens
Stephens says Santander Consumer may benefit if Wells pulling back on auto loans
05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
03/17/20 Barclays
Santander Consumer downgraded to Underweight from Equal Weight at Barclays
01/06/20 Stephens
Stephens upgrades Santander Consumer to Equal Weight ahead of expected buybacks
FSLY Fastly
$102.67 /

+6.52 (+6.78%)

07/10/20 BofA
Fastly double-downgraded to Underperform from Buy at BofA
07/10/20 BofA
Fastly downgraded to Underperform from Buy at BofA
07/09/20 Citi
Citi recommends overweight Zoom Video, underweight Fastly pair trade
07/09/20 Citi
Citi downgraded Fastly to Sell with stock up 400% in three months
RIG Transocean
$1.90 /

-0.12 (-5.96%)

07/08/20 Morgan Stanley
Morgan Stanley downgrades Transocean to Equal Weight on offshore drilling view
07/08/20 Morgan Stanley
Transocean downgraded to Equal Weight from Overweight at Morgan Stanley
07/02/20 Evercore ISI
Transocean secures contract for 20k PSI drillship, says Evercore ISI
06/15/20
Fly Intel: Top five analyst downgrades
CNTG Centogene
$17.06 /

-2.1 (-10.96%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

  • 10
    Jul
  • 21
    May
  • 05
    Feb
  • 07
    Nov
  • 01
    Aug
RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

On The Fly
Fly Intel: After-Hours Movers » 19:02
07/09/20
07/09
19:02
07/09/20
19:02
SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, PSMT

PriceSmart

$60.38 /

+0.895 (+1.50%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, IART

Integra LifeSciences

$46.22 /

-0.555 (-1.19%)

, WDFC

WD-40

$200.59 /

-2.48 (-1.22%)

, FC

Franklin Covey

$19.18 /

-1.125 (-5.54%)

, KERN

Akerna

$7.25 /

-0.21 (-2.82%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

05/08/20 Scotiabank
Scotiabank downgrades PriceSmart amid COVID-19 restrictions
05/08/20 Scotiabank
PriceSmart downgraded to Sector Perform from Outperform at Scotiabank
09/23/19 Kansas City Capital
PriceSmart downgraded to Perform from Outperform at Kansas City Capital
07/18/19
Fly Intel: Top five analyst upgrades
MATX Matson
$27.46 /

-0.69 (-2.45%)

04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

05/27/20
Fly Intel: Top five analyst initiations
05/27/20 Citi
Integra LifeSciences initiated with a Neutral at Citi
05/21/20 Piper Sandler
Early diligence on new Tactile Systems CEO very positive, says Piper Sandler
05/08/20 JMP Securities
Integra LifeSciences price target lowered to $65 from $75 at JMP Securities
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
03/27/20 DA Davidson
WD-40 upgraded to Buy from Neutral at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
01/07/20 DA Davidson
WD-40 downgraded to Neutral from Buy at DA Davidson
FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

04/03/20 Roth Capital
Franklin Covey price target lowered to $28 from $51 at Roth Capital
03/30/20 B. Riley FBR
Franklin Covey price target lowered to $32 from $45 at B. Riley FBR
01/30/20
Franklin Covey management to meet with Roth Capital
KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

IART Integra LifeSciences
$46.22 /

-0.555 (-1.19%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

  • 05
    Feb
WDFC WD-40
$200.59 /

-2.48 (-1.22%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

WDFC WD-40
$200.59 /

-2.48 (-1.22%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

PSMT PriceSmart
$60.38 /

+0.895 (+1.50%)

KERN Akerna
$7.25 /

-0.21 (-2.82%)

FC Franklin Covey
$19.18 /

-1.125 (-5.54%)

Hot Stocks
Ziopharm initiates Phase 1 trial evaluating CD19-specific CAR-T » 16:16
07/09/20
07/09
16:16
07/09/20
16:16
ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

Ziopharm Oncology…

Ziopharm Oncology announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center. In this trial, the company utilizes its non-viral Sleeping Beauty genetic engineering technology to infuse CAR-T the day after electroporation. Ziopharm's RPM CD19-specific CAR-T therapy results from the stable, non-viral insertion of DNA into the genome of resting T cells to co-express the chimeric antigen receptor, membrane-bound IL-15 and a safety switch.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

  • 05
    Feb
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

Hot Stocks
Ziopharm doses first patient with DIPG in Ad-RTS-hIL-12 study » 08:42
07/08/20
07/08
08:42
07/08/20
08:42
ZIOP

Ziopharm

$3.22 /

+ (+0.00%)

Ziopharm announced that…

Ziopharm announced that the first patient with diffuse intrinsic pontine glioma, or DIPG, has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

ZIOP Ziopharm
$3.22 /

+ (+0.00%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

  • 05
    Feb
ZIOP Ziopharm
$3.22 /

+ (+0.00%)

Over a month ago
Options
Unusual call flow in option market yesterday » 07:35
06/24/20
06/24
07:35
06/24/20
07:35
AAPL

Apple

$366.23 /

+7.15 (+1.99%)

, ETSY

Etsy

$101.31 /

+5.09 (+5.29%)

, ZIOP

Ziopharm

$3.57 /

+0.015 (+0.42%)

Notable call activity was…

Notable call activity was cited Tuesday in Apple (AAPL), Etsy (ETSY), and Ziopharm (ZIOP).

ShowHide Related Items >><<
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
06/23/20 Baird
Apple price target raised to $390 from $320 at Baird
06/23/20 Credit Suisse
Apple launches at WWDC more incremental than thesis-changing, says Credit Suisse
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
ETSY Etsy
$101.31 /

+5.09 (+5.29%)

06/23/20 RBC Capital
Etsy price target raised to $117 from $79 at RBC Capital
06/22/20 Goldman Sachs
Etsy price target raised to $120 from $88 at Goldman Sachs
06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 Jefferies
Etsy upgraded to Buy from Hold at Jefferies
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

ZIOP Ziopharm
$3.57 /

+0.015 (+0.42%)

ETSY Etsy
$101.31 /

+5.09 (+5.29%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

AAPL Apple
$366.23 /

+7.15 (+1.99%)

Options
Calls lead puts 11:1 in Ziopharm Oncology » 10:10
06/23/20
06/23
10:10
06/23/20
10:10
ZIOP

Ziopharm

$3.64 /

+0.08 (+2.25%)

Calls lead puts 11:1 in…

Calls lead puts 11:1 in Ziopharm Oncology. Shares up 10c, or nearly 3%, to $3.66 this morning with 1400 calls trading early, vs 120 puts and July 4 calls seeing most of the flow, including a 15c buyer of 522, followed by 20c for another 500.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

ZIOP Ziopharm
$3.64 /

+0.08 (+2.25%)

Hot Stocks
Ziopharm completes enrollment of Phase 2 trial of IL-12 with Libtayo » 08:32
06/22/20
06/22
08:32
06/22/20
08:32
ZIOP

Ziopharm

$3.34 /

+0.06 (+1.83%)

Ziopharm Oncology (ZIOP)…

Ziopharm Oncology (ZIOP) announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex in combination with the PD-1 inhibitor Libtayo for the treatment of recurrent or progressive glioblastoma in adults. Subjects in this multi-center trial were enrolled from seven hospitals specializing in the treatment of brain cancers across the United States. Ziopharm's Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12, a master-regulator of the immune system. In the setting of rGBM, the Company is leveraging the anti-tumor effects for Controlled IL-12 as a monotherapy and in combination with PD-1 inhibitors. Clinical data supporting the combination of Controlled IL-12 and a PD-1 inhibitor were initially published in Science Translational Medicine. Data from serial biopsies in patients with rGBM revealed that Controlled IL-12 results in the sustained influx of activated T cells and upregulation of PD-1 expression, providing a compelling rationale for this combination. Recently, additional data from a phase 1 trial were presented at the American Society of Clinical Oncology 2020 virtual meeting showing Controlled IL-12 in combination with a PD-1 inhibitor had a favorable safety profile and preliminary signs of anti-tumor efficacy. The open-label, single-arm phase 2 trial is designed to examine Controlled IL-12 in combination with cemiplimab in 36 patients with rGBM, with the primary endpoints being safety and efficacy. Patients with rGBM scheduled for resection, who have not been treated previously with immune checkpoint inhibitors, received Ad-RTS-hIL-12 intratumorally at the time of surgical resection plus 20 mg of veledimex, an oral activator of Ad-RTS-hIL-12, daily for 14 days. Patients will also receive cemiplimab intravenously every three weeks until documented progression or withdrawal from the study. Trial investigators may enroll additional patients currently in screening. In November 2018, Ziopharm and Regeneron entered a clinical supply agreement to evaluate combination therapy of Ziopharm's Controlled IL-12 with Regeneron's (REGN) PD-1 antibody cemiplimab to treat patients with rGBM.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

ZIOP Ziopharm
$3.34 /

+0.06 (+1.83%)

Initiation
Ziopharm initiated with a Buy at Jefferies » 06:00
06/19/20
06/19
06:00
06/19/20
06:00
ZIOP

Ziopharm

$3.28 /

+0.04 (+1.23%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Ziopharm Oncology with a Buy rating and $7 price target. While the company has a long history, it has a "new story with exciting" gene and cellular therapies for oncology, Howerton tells investors in a research note. The analyst sees "substantial upside" from clinical success in either of Ziopharm's programs, TCR-T in solid tumors and Ad-RTS-hIL12 in recurrent glioblastoma.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
03/03/20 Cantor Fitzgerald
Ziopharm initiated with an Overweight at Cantor Fitzgerald
ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

ZIOP Ziopharm
$3.28 /

+0.04 (+1.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.